Prasad BSV Chief Operating Officer Biocon Limited

Prasad BSV, Chief Operating Officer (COO), Biocon Limited, discussed the company’s growth strategy to add solid-dosage manufacturing capabilities to complement the company’s current position in injectable drug-product manufacturing and active pharmaceutical ingredient (API) development and manufacturing. He made the comments at the DCAT Week ’18 Member Company Announcement Forum, which was held Monday, March 19, 2018 in New York.

The COO outlined the company’s business activities and its recent expansion. Biocon has an established contract manufacturing business to provide a combination of complex fermentation and high potent technologies, process-development capabilities, and large-scale API manufacturing capabilities with multiple facilities in Bangalore, Hyderabad and Visakhapatnam, India.

As part of its growth strategy, Biocon has further expanded its drug-product manufacturing capabilities. In addition to its existing injectable facility, Biocon has established a new oral solid drug-product facility in Bangalore, India. This facility complements the existing capabilities of Biocon and enables it to manufacture niche, small-scale products and high potent products up to occupational exposure limits of Band-5. The potent line has a capacity of 100 million tablets or capsules, and the non-potent line has a capacity of 300 million tablets or capsules with scope for further expansion.

The COO explained that with the new facility, in addition to the company’s core competencies of complex technologies, large-scale API manufacturing capabilities and regulatory compliance, Biocon’s value creation encompasses forward integration to niche high potent and small-scale drug products.